Pimecrolimus 외용제(엘리델크림 1%)

· Harrison's Principles of Internal Medicine, 20e > Chapter 54: Skin Manifestations of Internal Disease > HYPOPIGMENTATION

· Fitzpatrick's Dermatology in General Medicine, 8e 2012 > Chapter 74. Vitiligo > Treatment

· Clinical Dermatology Sixth Edition 2016 > Chapter 19. Light-related diseases and disorders of pigmentation > DISORDERS OF HYPOPIGMENTATION >　Vitiligo

· A. Taieb, et al. Guidelines for the Management of Vitiligo. The European Dermatology Forum Consensus, 2012 British Association of Dermatologists 2013 168, pp5-19

· Naoki OISO, et al. Guidelines for the diagnosis and treatment of vitiligo in Japan, Journal of Dermatology 2013; 40: 344-354.

· A. Wollenberg, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I, JEADV 2018, 32, 657-682.

· Ichiro Katayama, et al. Japanese guidelines for atopic dermatitis 2017*, Allergology International 66 (2017) 230e247

· Bae JM, et al. The efficacy of 308-nm excimer laser/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: A systematic review and meta-analysis of randomized controlled trials (RCTs). J Am Acad Dermatol. 2016 May;74(5):907-15.

· Bapur Erduran F, et al. Comparison of the efficacy of 308-nm excimer lamp monotherapy with topical tacrolimus or clobetasol 17-propionate combination therapies in localized vitiligo. Photodermatol Photoimmunol Photomed. 2016 Sep;32(5-6):247-253.

· Sisti A, et al. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review. An Bras Dermatol. 2016 Apr;91(2):187-95.

· Park OJ, et al. A combination of excimer laser treatment and topical tacrolimus is more effective in treating vitiligo than either therapy alone for the initial 6 months, but not thereafter. Clin Exp Dermatol. 2016 Apr;41(3):236-41.

· Cavalie M, et al. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015 Apr;135(4):970-4.

· Ho N, et al. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0·1% vs. clobetasol propionate 0·05% in childhood vitiligo. Br J Dermatol. 2011 Sep;165(3):626-32.

· Majid I, et al. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study. Photodermatol Photoimmunol Photomed. 2010 Oct;26(5):230-4.

· de Menezes AF, et al. Pharmacologic Treatment of Vitiligo in Children and Adolescents: A Systematic Review. Pediatr Dermatol. 2017 Jan;34(1):13-24.

· Dang YP, et al. Effect of topical calcineurin inhibitors as monotherapy or combined with phototherapy for vitiligo treatment: a meta-analysis. Dermatol Ther. 2016 Mar-Apr;29(2):126-33.

· Roy P, et al. Effectiveness of Topical Corticosteroid, Topical Calcineurin Inhibitors and Combination of Them in the Treatment of Vitiligo. Mymensingh Med J. 2016 Oct;25(4):620-627.

· Dayal S, et al. Treatment of Childhood Vitiligo Using Tacrolimus Ointment with Narrowband Ultraviolet B Phototherapy. Pediatr Dermatol. 2016 Nov;33(6):646-651.

· Njoo MD, et al. Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol. 1998 Dec;134(12):1532-40.

· Lepe V, et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003 May;139(5):581-5.

· Farajzadeh S, et al. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study. Pediatr Dermatol. 2009 May-Jun;26(3):286-91.

· Shim WH, et al. A pilot study of 1% pimecrolimus cream for the treatment of childhood segmental vitiligo. Ann Dermatol. 2013 May;25(2):168-72.

· Kose O, et al. Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. J Dermatolog Treat. 2010 May;21(3):133-9.

· Dawid M, et al. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges. 2006 Nov;4(11):942-6.

· Kumaran MS, et al. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol. 2006 Mar;20(3):269-73.

· Esfandiarpour I, et al. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat. 2009;20(1):14-8.

· Kathuria S, et al. Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream. Indian J Dermatol Venereol Leprol. 2012 Jan-Feb;78(1):68-73.

· Westerhof W, et al. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. Arch Dermatol. 1999 Sep;135(9):1061-6.

· Coskun B, et al. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol. 2005 Mar-Apr;15(2):88-91.

· Jordi Castellsague, et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation · JOELLE study). Clinical Epidemiology 2018:10 299-310.

· David J, et al. Association Between Malignancy and Topical Use of Pimecrolimus. JAMA Dermatology Published online February 18, 2015.

· S. C. S. Cai, et al. Topical calcineurin inhibitors in eczema and cancer association: A cohort study. JOURNAL OF DERMATOLOGICAL TREATMENT, 2016.